Each PD-1 inhibitor exhibited varying rates of adverse events: The most common adverse events associated with Sintilimab were hypothyroidism, pneumonitis, anemia, and decreased white blood cell count. This evidence concerns the gene PDCD1 and anemia (phenotype).